All news

Amgen beats with $6.45 adjusted EPS, raises 2026 revenue guide to $38.9-$39.7 billion

Reuters · · AI-summarised by FinFlash

Amgen's third-quarter sales rose 8% to

So What?

The beat and raise support large-cap biotech sentiment, with newer drugs outrunning Prolia's decline. Watch tomorrow's reaction in AMGN and peers for confirmation.

Read original source

AMGN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.